6% for Italy to 53.9% for Germany) [23]. Since lack of coverage due to point mutations is less likely for strains expressing multiple vaccine antigens, the percentage of Greek strains covered by at least two vaccine antigens suggests that the rate of emergence of escape variants
in Greece is not expected to be different than in other European countries. More recently, a study on estimate of 4CMenB coverage of 157 Canadian serogroup B isolates circulating from 2006 to 2009 has also been published [24] In Canada, where the most frequent ccs were cc41/44 and cc269, Idasanutlin the overall 4CMenB MATS predicted coverage was 66%, slighly lower than in Greek and Euro-5 isolates, however results were similar to those found in England and Wales. Conclusions At present, there is an increasing number of reports published using MATS. Nevertheless, there has been, up to now, no data from Greece. Our data provide a good prediction of the potential coverage of 4CMenB in Greece similarly to other European countries, despite differences in the prevalence of MLST genotypes, such as cc162 and, as a consequence,
in the frequency and distribution of fHbp, NHBA LDK378 clinical trial and NadA protein peptides. However, our study argues for continuous surveillance by MATS typing that should allow “real-time” post-implementation estimates of coverage. Authors’ information GT PhD, Head, National Meningitis Reference Laboratory, National School of Public Health Athens, Greece. EH BSc Institute Pasteur, Invasive Bacterial Infections Unit, Paris, France. KK PhD National Meningitis Reference Laboratory, National School of Public Health
Athens, Greece. AX PhD National Meningitis Reference Laboratory, National School of Public Health Athens, Greece. SB PhD Novartis Vaccines and Diagnostics, Siena, Italy. LO Msc Novartis Vaccines and Diagnostics, Siena, Italy. MC PhD Novartis Vaccines and Diagnostics, Siena, Italy. AM PhD Novartis Vaccines and Diagnostics, Siena, Italy. M-KT MD, PhD Institute Pasteur, Head, Invasive Staurosporine solubility dmso Bacterial Infections Unit, Paris, France. Acknowledgements The study was supported by grants obtained from the National School of Public Health through the Hellenic Centre for Disease Control and Prevention, Pasteur Institute, France and Novartis Vaccines. Disclosed conflicts of interest M-KT has acted as a consultant for received travel support from GalxoSmithKline, Novartis, Pfizer and Sanofi Pasteur, and has undertaken contract research on behalf of the Institut Pasteur Paris, France, for Novartis, Pfizer and Sanofi Pasteur. GT has acted as a consultant for received travel support from GalxoSmithKline, Novartis, and Pfizer. SB, LO, AM are NOVARTIS employees. MC was a NOVARTIS employee at the time in which the data were generated. EH, KK, AX no conflict of interest. References 1. Stephens DS, Greenwood B, Brandtzaeg P: Epidemic meningococcaemia, and Neisseria meningitidis .